STROBE Statement—Checklist of items that should be included in reports of ***cross-sectional studies***

	Item No	Recommendation	Page No
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	p1
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	p2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	p3-4, lines 53-88
Objectives	3	State specific objectives, including any prespecified hypotheses	p4, lines 82-88
Methods			
Study design	4	Present key elements of study design early in the paper	p4, lines 91-96
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	p4-6, lines 94-105; 115-125.
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of selection of participants	p5, lines 107-113
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	p5, lines 115-125; Appendix A-B
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	p5, lines 115-125; Appendix A-B
Bias	9	Describe any efforts to address potential sources of bias	p6, lines 127-130
Study size	10	Explain how the study size was arrived at	p5-6, lines 98-113;119-125.
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	p6, lines 127-132.
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding	p6, lines 127-132.
		(*b*) Describe any methods used to examine subgroups and interactions	N.A.
		(*c*) Explain how missing data were addressed	p6, lines 127-130.
		(*d*) If applicable, describe analytical methods taking account of sampling strategy	p6, lines 127-130. Unknown responses are reported (e.g. see Figure 1; Table A2)
		(*e*) Describe any sensitivity analyses	N.A.
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	p5, lines 104-105; 112-113, 119-121.

		(b) Give reasons for non-participation at each stage	p5-6, lines 120-121
		(c) Consider use of a flow diagram	N.A.
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	p6 lines 135-145; Table A1
		(b) Indicate number of participants with missing data for each variable of interest	Unknown responses are reported (e.g. see Figure 1; Table A2)
Outcome data	15*	Report numbers of outcome events or summary measures	p7, lines 147-163; Figure 1-2
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	No adjusted estimates; 95% confidence intervals presented throughout.
		(*b*) Report category boundaries when continuous variables were categorized	N.A.
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N.A.
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Appendix Table A3
Discussion			
Key results	18	Summarise key results with reference to study objectives	p8, lines 166-172
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	p8-9, lines 174-190
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	p9-10, lines 192-222
Generalisability	21	Discuss the generalisability (external validity) of the study results	p8, lines 183-190.
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	N.A.

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.